How should a solid tumor be managed from diagnosis through staging and treatment?

Management of Solid Tumors: Diagnosis Through Treatment

All solid tumors require immediate multidisciplinary team (MDT) management with histological diagnosis via core needle biopsy before any definitive treatment, followed by comprehensive staging and tumor-specific therapy based on grade and stage. 1

Initial Diagnostic Approach

Immediate Referral Criteria

• Any unexplained lump increasing in size warrants ultrasound within 2 weeks 1
• Ultrasound findings suggestive of malignancy or uncertain findings with persistent clinical concern require suspected cancer pathway referral 1
• Critical pitfall: Retroperitoneal or intra-abdominal masses must be referred to specialist MDT before biopsy or surgery to avoid contamination of tissue planes 1

Tissue Diagnosis

Obtain pre-treatment histopathological diagnosis via percutaneous core needle biopsy (multiple cores, not fine-needle aspiration), reviewed by specialist pathologist 2, 1. The biopsy should be performed at the reference center by the surgeon performing definitive resection, a radiologist, or team member 3.

Key biopsy principles:

• Minimize contamination of normal tissues
• Use longitudinal incision if open biopsy required
• Include biopsy tract in subsequent resection 2, 3
• Send samples for histology, immunohistochemistry, cytogenetics, and molecular analysis 2, 1
• Never perform excisional biopsy for aggressive-benign or malignant lesions—this contaminates tissue compartments unnecessarily 3

Specific Tumor Identification

• Gastrointestinal stromal tumors: confirm with CD117 staining 2
• Small round cell tumors (Ewing's sarcoma, rhabdomyosarcoma): identify via immunohistochemistry and cytogenetics 2
• Histological grading is essential and preferably uses FNCLCC system (differentiation, necrosis, mitotic rate) 1

Staging Protocol

Local Staging

MRI of the entire affected bone/extremity with adjacent joints is the gold standard for local staging 3, 1. Plain radiographs in two planes should always be first, followed by MRI when malignancy cannot be excluded 3.

For soft tissue sarcomas, staging categorizes:

• Tumor size: ≤5 cm (T1) vs >5 cm (T2)
• Location: superficial (Ta) vs deep (Tb)
• Histological grade: G1-4 or low/high 2

Systemic Staging

Mandatory staging includes:

• CT chest to exclude lung metastases in all operable patients 2, 3
• Bone scintigraphy 3, 4
• Physical examination for regional/local lymph nodes 3
• Consider whole-body MRI and PET-CT/PET-MRI for comprehensive assessment 4

Treatment Algorithm

Localized Disease

Surgery is the primary treatment for all localized solid tumors 2, 1. The tumor must be removed by wide excision or compartmental resection, including the cutaneous scar and biopsy tract 2.

Surgical Principles:

• Performed by surgeon with appropriate sarcoma training 1
• Complete excision with margin of normal tissue
• Resection width may be decreased at resistant anatomic planes (muscular fasciae, periosteum, perineurium) if not infiltrated 2
• Plastic surgical reconstruction should be coordinated with resection and radiation teams 1

Adjuvant Radiation Therapy:

• Required after wide excision of high-grade sarcomas 2
• Not necessary after radical surgery via compartmental excision or amputation at large distance from primary tumor 2
• Should be given with inadequate surgical margins or poor histological response 4

Chemotherapy Considerations:

• Preoperative chemotherapy is NOT standard practice for operable patients 2
• May be considered with radiotherapy for borderline resectable tumors 2
• Adjuvant chemotherapy is NOT standard practice despite potential improvement in distant/local control; overall survival benefit remains debated 2
• Consider in younger patients with large, high-grade tumors 2

Re-operation:

Re-operation is recommended for previous marginal or intralesional resection 2

Non-Resectable Extremity Tumors

For tumors confined to an extremity, chemotherapy ± radiotherapy or isolated hyperthermic limb perfusion with chemotherapy/cytokines offers alternative to amputation 2

Metastatic Disease

Chemotherapy is standard treatment for metastatic disease, typically doxorubicin with or without ifosfamide 2.

For completely resectable lung metastases, surgery must be considered 2. This applies even in metastatic setting, as surgical resection of isolated lung metastases can be curative 2.

Response evaluation should occur after 2-3 cycles using radiological exams positive before treatment 2.

Follow-Up Protocol

Structured surveillance detects recurrence when curative therapy remains possible 2:

• Every 3 months: History and physical examination
• First 2-3 years:
  • MRI of resection site twice yearly, then annually
  • Chest X-ray every 3-4 months for high-grade tumors
• Years 3-5: Chest X-ray twice yearly for high-grade tumors
• After 5 years: Annual chest X-ray for high-grade tumors 2

Critical Pitfalls to Avoid

1. Never biopsy retroperitoneal/intra-abdominal masses before MDT review—refer first 1
2. Never perform excisional biopsy for suspected malignant lesions 3
3. Never skip chest CT in operable patients—lung metastases change management 2
4. Never allow non-specialist surgeons to perform initial resection—inadequate margins necessitate re-operation and worsen outcomes 2, 1
5. Core needle biopsy may underestimate tumor grade due to heterogeneity—correlate with imaging 1

The most recent UK guidelines 1 emphasize that all management decisions must occur within a formally constituted sarcoma MDT, ensuring optimal surgery, chemotherapy, radiotherapy timing, clinical trial recruitment, and accurate outcome data collection.